Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
Medtech in 2028: Suffering or celebrating a Covid hangover?
We've extended our forecasts out to 2028 and in our latest report, we take a look at what's in store for the medtech market in the next few years.
Five things you’re getting wrong in your pipeline planning
R&D pipelines are the lifeblood of the pharma industry - so why are we still getting it wrong?
Evaluate Vantage Podcast: Glimmers of Hope or Fool's Gold?
The Evaluate Vantage team have hit the podcast studio again to discuss the good, the bad and the ugly of the pharma and medtech world
Patient centricity: the unexpected legacy of Covid-19
The world is a long way from understanding the true and far-reaching legacy of Covid-19. While debate regarding the handling of the pandemic will continue, there are…
Demystifying AI: Natural Language Processing (Part Two)
Natural language processing (NLP) is a key component of many machine learning approaches. We've looked at (broadly) how it works, now we investigate some of they key…
Demystifying AI: Natural Language Processing (Part One)
Machine learning and artificial intelligence are increasingly-used buzzwords in the pharma and biotech space. But what's hiding in that black box?
Biotech Investment in 2022 : “You’ve got to kiss a lot of frogs”
The market may be tough, but with unprecedented innovation taking place, there's plenty for biotechs and investors to feel positive about in the long term
Q3 catalysts podcast: Evaluate Vantage hits the airwaves
Got time for a quick brain break? Listen to our podcast where we discuss the catalysts that will shape the third quarter of 2022.
BIO International 2022: Words from Space and Venus
Bio International was finally back for 2022. What did our first-timer to the event make of it?